Lou Hawthorne's keynote introduced NaNotics, a biotechnology company developing a novel class of medicine called "Nanot." Nanots target soluble factors in the blood that contribute to diseases like cancer and inflammation. Unlike conventional drugs that target cells, Nanots deplete these circulating factors, helping to reset the body’s signalling systems and enhance immune responses. The technology shows great potential for treating cancer, autoimmune diseases like rheumatoid arthritis, and sepsis, with future applications in managing ageing-related conditions.

Key Points:

• NaNotics' Nanot technology: A new type of therapy that removes disease-driving soluble factors in the bloodstream, offering a unique approach to treating cancers and inflammatory conditions​.
• Cancer therapies: Nanots remove immune inhibitors produced by tumors, uncloaking them for destruction by the immune system, showing improved outcomes in hard-to-treat cancers​.
• Inflammation targeting: Nanots target inflammatory cytokines like TNF and IL-6, potentially offering a more effective treatment for diseases like rheumatoid arthritis.
• Rapid depletion: Nanots quickly deplete harmful soluble factors in minutes without affecting healthy cells, offering fast-acting solutions​.
• Adaptable platform: NaNotics' modular platform can be customized to target different diseases by swapping capture agents for specific soluble factors​.
• Future potential: The technology could be expanded to tackle sepsis, one of the deadliest medical conditions, by targeting the inflammatory cytokines that drive it​.